Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi

Incyte Corporation (INCY) announced that the FDA has approved a label expansion of its lead drug, Jakafi (ruxolitinib).

Jakafi is now approved for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.